# Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

> **NCT05332925** · — · RECRUITING · sponsor: **Jun Zhang, MD, PhD** · enrollment: 25 (estimated)

## Conditions studied

- Lung Cancer
- NSCLC
- NSCLC Stage IV

## Interventions

- **DRUG:** Standard of care immune checkpoint inhbitors

## Key facts

- **NCT ID:** NCT05332925
- **Lead sponsor:** Jun Zhang, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-21
- **Primary completion:** 2026-01
- **Final completion:** 2027-02
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05332925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05332925, "Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05332925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*